TTI-101
- Generic Name
- TTI-101
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H21NO5S
- CAS Number
- 432001-19-9
- Unique Ingredient Identifier
- KZ3DLD11RQ
- Associated Conditions
- -
- Associated Therapies
- -
Trial of Radiotherapy in Combination with TTI-101 in Patients with Borderline Resectable Pancreatic Cancer
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 35
- Registration Number
- NCT06141031
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT05845307
- Locations
- 🇺🇸
M D Anderson Cancer Centerl, Houston, Texas, United States
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 75
- Registration Number
- NCT05671835
- Locations
- 🇺🇸
The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸University of California Irvine (UCI) Health, Orange, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT05668949
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 166
- Registration Number
- NCT05440708
- Locations
- 🇺🇸
The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 6
- Registration Number
- NCT05384119
- Locations
- 🇺🇸
Holy Cross Health Fort Lauderdale - Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT03195699
- Locations
- 🇺🇸
Mays Cancer Center at University of Texas Health Science Center SA, San Antonio, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.